Clinical trials: Cannabidiol
Schizophrenia
Enhancing Recovery in Early Schizophrenia
Current antipsychotic treatments of schizophrenia are only partially effective, and their use is often associated with serious side effects.
- Trial name
- NCT02926859
- Testing
- Cannabidiol as add-on
- Where
- 6 sites in Germany
- Volunteers
- 180 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Osteoarthritis, Knee, Pain
Osteoarthritis of the Knee Pain Study Using a CBD and THC Sublingual Tablet
This study is a prospective Phase 2, drug controlled, open-label study to evaluate the safety and efficacy of Pure Green sublingual tablets for the treatment of pain associated with osteoarthritis of the knee.
- Trial name
- NCT04195269
- Testing
- Test Article
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pure Green
Healthy, Safety Issues
Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults
The purpose of this prospective, randomized, double-blind, placebo-controlled trial is to assess the physiological, biochemical, and psychometric impacts of a brand-specific hemp-derived cannabidiol product in a sample of healthy…
- Trial name
- NCT05212402
- Testing
- Cannabinol
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Drug Interaction
Cannabidiol and CES1 Interactions in Healthy Subjects
The proposed study will assess the drug interaction potential between oral cannabidiol (Epidiolex®) and the carboxylesterase 1 (CES1) substrate methylphenidate (Ritalin®) in 12 healthy research subjects
- Trial name
- NCT04603391
- Testing
- dl-Methylphenidate plus Cannabidiol
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Florida
Breast Cancer Stage I, Breast Cancer Stage II
Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer
Phase III, single-center, randomized, double-blind, placebo-controlled, 2x2 cross- over study, assessing the efficacy of CBD in patients with early HR+ BC, presenting aromatase inhibitor-related musculoskeletal pain
- Conditions
- Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, HR+ Breast Cancer
- Trial name
- PANDORA (NCT06787118)
- Testing
- CBD oil
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Bipolar Disorder, Bipolar Depression
Cannabidiol as an Adjunctive Treatment for Bipolar Depression
Depressive symptoms are associated with significant psychosocial impairment. However, current treatments of bipolar depression are only partially effective.
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar Affective Disorder
- Trial name
- CBDBD (NCT03310593)
- Testing
- Cannabidiol
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Autism Spectrum Disorder
The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Data on the effects of cannabidiol rich cannabis extract use for ASD is promising but still limited.
- Trial name
- NCT05212493
- Testing
- Cannabis oil
- Where
- Israel
- Volunteers
- 128 people
- Sponsor
- Assaf-Harofeh Medical Center
Hereditary Epidermolysis Bullosa
Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa
Hereditary epidermolysis bullosa (HEB) is a heterogeneous group of rare genetic diseases, characterized by fragility of the skin and mucous membranes, which results in the appearance of mucocutaneous bullae and erosions during…
- Trial name
- EBCBD (NCT05651607)
- Testing
- Cannabidiol
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neck Pain
Therapy With Paravertebral Oxygen-ozone Injections and Topical Cannabidiol and β-Caryophyllene Patch in Neck Pain
The aim of this study is to compare the effectiveness of combined treatment with paravertebral oxygen-ozone injections and topical patches containing Cannabidiol and β-Caryophyllene in patients with neck pain by evaluating the…
- Trial name
- NCT06099171
- Testing
- Cannabidiol and β-Caryophyllene Patch, Oxygen-Ozone Therapy
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Humanitas Clinical and Research Center
Cancer
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study
To collect information about how patients in the pain management clinic use cannabis/CBD, including how often it is used, why it is used (for example, to manage pain or other symptoms), and where patients get their information on…
- Trial name
- NCT05836857
- Testing
- Cannabis (Marijuana), Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Cannabidiol Pharmacokinetics
The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol
This study will evaluate the pharmacokinetics and pharmacodynamics of cannabidiol administered via inhalation and oral ingestion.
- Trial name
- NCT03164512
- Testing
- Oral or vaporized cannabidiol
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alcohol Use Disorder, Post Traumatic Stress Disorder
Cannabidiol as a Treatment for AUD Comorbid With PTSD
This project aims to determine whether cannabidiol (CBD), a compound derived from the cannabis plant, is effective in treating alcohol use disorder (AUD) in individuals with comorbid posttraumatic stress disorder (PTSD).
- Trial name
- NCT03248167
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Anxiety
A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in adults. Participants will use a custom-formulated sublingual (under-the-tongue) solution of whole plant, hemp-derived CBD twice daily…
- Trial name
- NCT04286594
- Testing
- CBD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mclean Hospital
Diabetic Peripheral Neuropathic Pain
Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet
The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.
- Trial name
- NCT04679545
- Testing
- CBD
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Pure Green
Diabetic Peripheral Neuropathic Pain
Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA
The purpose of the study is to evaluate whether the DIA/NPR-6 is a better pain reliever in patients with diabetic neuropathic pain of the feet compared to placebo.
- Trial name
- NCT05766969
- Testing
- CBD/PEA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Pure Green Pharmaceuticals Inc.
Opioid Use Disorder, Methadone
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid…
- Conditions
- Opioid Use Disorder, Methadone, Cannabis, Fentanyl
- Trial name
- THC-MMT (NCT05985850)
- Testing
- Aurora 1:1 Drops (Indica)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- BC Centre on Substance Use
Alcohol Use Disorder
Cannabidiol and Alcohol Use Disorder Phenotypes
The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.
- Trial name
- CAP (NCT07279558)
- Testing
- Full-Spectrum Cannabidiol (CBD), Broad-Spectrum Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Colorado, Denver
Anxiety, Epilepsy
Epidiolex® for Anxiety in Pediatric Epilepsy
This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult…
- Trial name
- NCT05324449
- Testing
- Cannabidiol 100 MG/ML
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Healthy Participants
A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol
The purpose of the study is to evaluate the pharmacodynamic (PD) interaction between steady-steady treatment with padsevonil (PSL) and Ethanol and the pharmacokinetic (PK) interaction between stead-state treatment with PSL and…
- Trial name
- NCT04039919
- Testing
- Padsevonil
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.